Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289421 | 1.00 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL430949 | 0.96 | — | — | |
| SCHEMBL30621784 | 0.88 | CA2 (0.34) | — | |
| SCHEMBL1041150 | 0.88 | CA2 (0.34) | — | |
| SCHEMBL10158608 | 0.84 | HSD17B10 (0.35) | — | |
| SCHEMBL7698403 | 0.82 | — | — | |
| SCHEMBL2992565 | 0.82 | — | — | |
| SCHEMBL17585473 | 0.82 | — | — | |
| SCHEMBL2355451 | 0.82 | TSHR (0.56) | MEN1KMT2A | |
| SCHEMBL14899281 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12573565-B1 | Calf-20 metal-organic framework for supercapacitor application | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2026-03-10 | — | — | US | disclosed |
| CN-118398302-A | Conductive film processing method, processing device and conductive film | 重庆金美新材料科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-114231886-B | High-temperature long-life YSZ coating and preparation method thereof | 西南科技大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-116322977-A | Photocatalytic titanium dioxide with multi-element impurities and production method | PCN材料公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-112285141-B | Preparation method of irradiated reactor structural material SEM sample and sample box | 中国核动力研究设计院 | 2022-09-13 | — | — | CN | disclosed |
| CN-114231886-A | High-temperature long-life YSZ coating and preparation method thereof | 西南科技大学 | 2022-03-25 | — | — | CN | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| US-9394313-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | MEN1 3693/4885KMT2A 440/4885 |
| US-20120065399-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | MEN1 3693/4885KMT2A 440/4885 |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | HVCN1, KCNQ4, KCNQ5 | MEN1 3693/4885KMT2A 440/4885 |
| US-12573565-B1 | Calf-20 metal-organic framework for supercapacitor application | F10, FOS, CTCF | MEN1 4509/4885KMT2A 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.